Navigation Links
The only European researcher to win this year's Early Career Bayer Hemophilia Award is Portuguese
Date:7/13/2011

Vanessa Oliveira, researcher at the Instituto de Medicina Molecular in Portugal won a prestigious and competitive Early Career Bayer Hemophilia Award. Oliveira will develop a strategy to reprogramme the immune system of hemophilia patients to avoid immune targeting of the most used clotting therapeutics. Oliveira was the only European researcher to win this award in 2010, in a total of 5 worldwide. The Portuguese researcher will receive US$170.000 to develop her project during two years.

Vanessa Oliveira will develop a strategy to reprogramme the immune system of hemophilia patients to avoid immune targeting of the most used clotting therapeutics. The treatment of hemophilia is based in the administration of laboratory produced clotting factors that the patients cannot make due to a genetic defect. However, a significant proportion of patients with severe hemophilia develop immune responses against these therapeutic clotting factors, which limits the efficacy of the treatment.

Although there have been several attempts to impair this undesired immune response, none of them has revealed efficient. Vanessa will study the causes for the limited efficacy of previously attempted methods to suppress undesirable immune response in hemophilia treatment, while developing new strategies to induce the patient's immune tolerance towards therapeutic clotting factors. This is a basic research project that will be developed in an animal model (mouse).

If results are promising, the project will be further developed to clinical studies. If Vanessas basic research is successful, it may help to improve the efficacy of current treatments. The project will be fully developed in Portugal, at the IMM's Cellular Immunology Unit, led by researcher Luis Graca.

The IMM's Cellular Immunology Unit has been developing cutting edge research in the area of immune-mediated diseases, such as asthma, transplantation and autoimmunity. The Unit's research has already resulted in the formation of a star-up company to develop a novel therapy to prevent liver transplant rejection.


'/>"/>

Contact: Marta Agostinho
marta-elisa@fm.ul.pt
351-918-486-058
Instituto de Medicina Molecular
Source:Eurekalert

Related medicine news :

1. Your e-Marketing Journey in 2010: An e-Book for Corporate Communicators Working in European Headquarters
2. United Therapeutics Corporation Withdraws European Marketing Authorization Application for Tyvaso for the Treatment of Pulmonary Arterial Hypertension
3. International Collaboration: FDA and European Medicines Agency Agree to Accept a Single Orphan Drug Designation Annual Report
4. Yondelis(R) Receives Five New Approvals Outside the European Economic Area
5. Promega Maxwell 16 IVD System CE Marked to the European Union IVD Directive Delivers Combined Solution for Infectious Disease
6. The European Medicines Agency Completes Validation Stage for InterMunes Marketing Authorization Application for pirfenidone
7. European hematologist receives award to conduct research in US
8. European collaboration seeks to create World Wide Web for robots
9. HCL Thames Medics says more locum doctors could help address European Working Time Directive shortage
10. Third European Novel Food Approval Received by Tahitian Noni International
11. European Urology: Editorial about REDUCE trial underlines value of dutasteride
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... ... February 17, 2017 , ... Teaching nursing care of vulnerable children is the ... (pediatrics) is being created with the support of the Hearst Foundations. An initiative of ... will address what has been identified as a critical gap in preparing the next ...
(Date:2/16/2017)... ... February 16, 2017 , ... As a reflection of ... care, NWH has achieved Magnet® recognition for the second time, announced ... The American Nurses Credentialing Center’s Magnet Recognition Program® distinguishes organizations that meet rigorous ...
(Date:2/16/2017)... ... February 16, 2017 , ... PRESS RELEASE, FOR ... , David A Doege is excited to announce the launch of Doege ... up new builds, design build, and site improvements. , Mr. Doege says, "I ...
(Date:2/16/2017)... ... 16, 2017 , ... A February 6 article on World Health.net ... noting that some 425,000 procedures were performed with the new technology in 2015. ... fact, seeing a great deal of interest from area patients who are seeking out ...
(Date:2/16/2017)... ... 2017 , ... Anahata Ananda of Shamangelic Healing, Sedona ... healing and society on the widely followed Aubrey Marcus Podcast in Austin, TX. ... many, the challenges facing them today can be daunting. In this episode, "Healing ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... (NYSE, TASE: PRGO) today announced it has received final approval ... and homatropine methylbromide oral solution (syrup), 5 mg/1.5 mg per ... oral solution (syrup), 5 mg/1.5 mg per 5 mL is ... children 6 years of age and older. Annual sales for ...   ...
(Date:2/17/2017)... , Feb. 17, 2017  In partnership with ... Friends for Good Health , The Jack Brewer ... filled with millions of dollars, worth of medicine to ... Haiti . IHI is a non-profit dedicated to treating ... is extremely active in Haiti ...
(Date:2/17/2017)... February 17, 2017 On Thursday, ... 500 edged lower at the closing bell, while the ... the 20,000 benchmark. Moreover, five out of nine sectors ... consideration yesterday,s market sentiment, Stock-Callers.com assessed the following Medical ... PLC (NYSE: SNN ), ABIOMED Inc. (NASDAQ: ...
Breaking Medicine Technology: